1. Robert O. Dillman, Gabriel I. Nistor & Hans S. Keirstead (2023) Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines, Human Vaccines & Immunotherapeutics, DOI: 10.1080/21645515.2023.2198467
  2. Piccioni DE, Duma CM, Kesari S, LaRocca RV, Aiken RD, et al. (2022) Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma. J Oncol Res Ther 7: 10149. DOI:
  3. Ascierto PA, Fox B, Urba W, Anderson AC, Atkins MB, Borden EC, Brahmer J, Butterfield LH, Cesano A, Chen D, de Gruijl T, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi F, Hwu P, Kaufman D, Kaufman H, Lotze M, McNeel DG, Margolin K, Marincola F, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wiggington JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 Apr;8(1)
  4. Nistor GI, Dillman RO. Cytokine network analysis of immune responses before and after therapeutic vaccine immunotherapies in a randomized trial in patients with metastatic melanoma. J Transl Med 18:176, 2020.
  5. Dillman RO, McClure SE. Cancer registry survival data for metrics of continuous quality improvement and quality assurance. Clin Oncology Res 2020;3:4-10.
  6. Dillman RO, Nistor GI, Poole AJ. Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine. Hum Vaccin Immunother Nov 15:1-14, 2019.
  7. Dillman RO, Hsieh C. Survival comparison between melanoma patients treated with patient-specific dendritic cell vaccines and other immunotherapies based on extent of disease at the time of treatment. Biomedicines Tumor Immunol Immunother 7(4), 80, 2019.
  8. Dillman RO. The resurgence of interest in anti-cancer dendritic cell vaccines. Am J Biomed Sci & Res. 5(3), 2019.
  9. Dillman RO, Nistor GI, McLelland BT, Hsieh C, Poole AJ, Cornforth AN, Keirstead H. Preliminary observations on soluble programmed death protein-1 (sPD1) as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines. Oncotarget 10:5359-5371, 2019.
  10. Dillman RO, Cornforth AN, McClay EF, Depriest C. Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Manag May 31;6(2):MMT20, 2019.
  11. Dillman RO, Hsieh C, Nistor GI. A clinical odyssey: cancer stem cells as the antigen source for autologous cancer vaccines. Adv Stem Cell Res 1(1):1-13, 2019.
  12. Dillman RO. Commentary: Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. J Vaccinology 1(1):1-4, 2019.
  13. Dillman RO, Depriest C. Dendritic cell vaccines presenting autologous tumor antigens from self-renewing cancer cells in metastatic renal cell cancer. J Exploratory Res Pharmacol 3:93-101, 2018.
  14. Dillman RO, Cornforth AN, McClay EF, Amatruda TT, Depriest C. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in patients with metastatic melanoma: 5-year follow up and additional analyses. J Immunother Cancer 6:19, 2018.
  15. Dillman RO. An update on the relevance of vaccine research for the treatment of metastatic melanoma. Melanoma Manag 4(4):203-215, 2017.
  16. Dillman RO. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother. 13(3):528-532, 2017.
  17. Dillman RO, Dennis-Beron S. Melanoma vaccines and viral-based immunotherapies: a special focus issue from Melanoma Management. Melanoma Manag. 2016 Dec;3(4):245-246.
  18. Dillman RO, Cornforth AN, Nistor GI. Dendritic cell vaccines for melanoma: past, present, and future. Melanoma Manag 3(4):273-289, 2016.


  1. McLelland BT, Lin B, Mathur A, Aramant RB, Thomas BB, Nistor G, Keirstead HS, Seiler MJ. Transplanted hESC-Derived Retina Organoid Sheets Differentiate, Integrate, and Improve Visual Function in Retinal Degenerate Rats. Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2586-2603.


  1. Dillman RO, Nistor GI, Jonny J, Yana ML, Langford JL, et al. (2023) Prevention of Symptomatic Covid-19 Infection by Personal Dendritic Cell Vaccine. J Vaccines Immunol 8: 189. DOI:
  2. Gabriel I. Nistor, Robert O. Dillman, Rockelle M. Robles, James L. Langford, Aleksandra J. Poole, Muchlis A. U. Sofro, Yetty M. Nency, Jonny Jonny, Martina L. Yana, Mahammad Karyana, Endang S. Lestari, Ria Triwardhani, Mujahidah Mujahidah, Retty K. Sari, Nur A. Soetojo, Djoko Wibisono, Daniel Tjen, Taruna Ikrar, Gregory Sarkissian, Haryono Winarta, Terawan A. Putranto & Hans S. Keirstead (2022) A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses, Human Vaccines & Immunotherapeutics, DOI: 10.1080/21645515.2022.2100189
  3. Robert O Dillman, Gabriel I Nistor, Aleksandra J Poole, A Novel Vaccine for The Novel Corona Virus. Am J Biomed Sci & Res. 2020 – 11(3). AJBSR.MS.ID.001631. DOI: 10.34297/AJBSR.2020.11.001631